Logo image
Back
Effects of low dose enoximone for chronic congestive heart failure
Journal article   Peer reviewed

Effects of low dose enoximone for chronic congestive heart failure

Mariell Jessup, Susan Ulrich, Judianne Samaha and Denise Helfer
The American journal of cardiology, v 60(5), pp 80-84
1987
DOI: https://doi.org/10.1016/0002-9149(87)90532-7
PMID: 2956875
Featured in Collection :   UN Sustainable Development Goals @ Drexel

Abstract

To examine the short-term hemodynamic and long-term clinical effects of oral enoximone at low doses, 12 patients with severe, chronic congestive heart failure (CHF) were given 1 mg/kg oral enoximone and followed with serial hemodynamic measurements for 24 hours. Control cardiac index was 1.9 ± 0.5 liters/min/m 2 and it increased significantly by 1 hour, with a peak effect at 2 hours to 2.4 ± 0.4 liters/min/m 2 (p < 0.05). Similarly, wedge pressure, 22 ± 8 mm Hg at control, decreased to 16 ± 10 by 1 hour (p < 0.05). Six of the 12 patients received 1 mg/kg of enoximone on day 1 and 2 mg/ kg on day 2. The higher dose of enoximone caused no further improvement in cardiac performance but prolonged the salutary hemodynamic effect. Subsequently, 79 patients (18 in New York Heart Association class III and 61 in class IV) with CHF (ejection fraction 17 ± 8%) were followed over a 3 year period; the average enoximone dose was 1.7 ± 0.7 mg/kg 3 times daily. Improvement of at least 1 functional class occurred in 55 patients (70%) at 1 month, 27 patients (34%) at 6 months and 19 (24%) maintained their improvement for over 1 year. Enoximone was discontinued in 20 patients (25%); in 5 (6%) for adverse effects and in 13 patients because of no clinical benefit. Adverse effects occurred in 14 patients (18%); 6% of all patients required discontinuation of drug. Six month survival was 50%, 42% at 1 year and 30% at 2 years. Oral enoximone at a dosage of 1 to 2 mg/kg 3 times daily caused an acute and significant improvement in cardiac performance and appeared to provide a sustained clinical benefit to patients with chronic CHF.

Metrics

10 Record Views
12 citations in Web of Science
14 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Cardiac & Cardiovascular Systems
Logo image